aluates Reports

$ 0.0

Automative

Global Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Market Research Report 2025

Published Date: June 2025

Report Code: QYRE-Auto-3D6158

Global Angioimmunoblastic T Cell Lymphoma AILT Treatment Market Insights Forecast to 2028

BUY CHAPTERS

Global Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Market Research Report 2025

Code: QYRE-Auto-3D6158

Report

June 2025

Pages:71

QYResearch

Buy Now with 15% Discount

DESCRIPTION

TABLE OF CONTENT

TABLES & FIGURES

FEATURED COMPANIES

Roche

Novartis

Seattle Genetics

Merck

Bristol–Myers Squibb

Genmab AS

Takeda Pharmaceutical

Eisai Co Ltd

Cellerant Therapeutics

Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Market Size

The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years.

Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Market

The global market for Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment was valued at US$ million in the year 2024 and is projected to reach a revised size of US$ million by 2031, growing at a CAGR of %during the forecast period.

The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

This report aims to provide a comprehensive presentation of the global market for Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment.

The Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.

For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

The report will help the Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

Market Segmentation

Scope of Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Market Report

Report Metric	Details
Report Name	Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Market
CAGR	5%
Segment by Type	Chemotherapy Radiation Therapy Others
Segment by Application	Hospitals Clinics Ambulatory Surgical Centers Others
By Region	North America (United States, Canada) Europe (Germany, France, UK, Italy, Russia) Rest of Europe Nordic Countries Asia-Pacific (China, Japan, South Korea) Southeast Asia (India, Australia) Rest of Asia Latin America (Mexico, Brazil) Rest of Latin America Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company	Roche, Novartis, Seattle Genetics, Merck, Bristol-Myers Squibb, Genmab AS, Takeda Pharmaceutical, Eisai Co., Ltd., Cellerant Therapeutics
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.

FAQ for this report

Who are the main players in the Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Market report?

Ans: The main players in the Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Market are Roche, Novartis, Seattle Genetics, Merck, Bristol-Myers Squibb, Genmab AS, Takeda Pharmaceutical, Eisai Co., Ltd., Cellerant Therapeutics

What are the Application segmentation covered in the Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Market report?

Ans: The Applications covered in the Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Market report are Hospitals, Clinics, Ambulatory Surgical Centers, Others

What are the Type segmentation covered in the Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Market report?

Ans: The Types covered in the Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Market report are Chemotherapy, Radiation Therapy, Others

Recommended Reports

Lymphoma & Leukemia Therapies

Cell & Immunotherapy Markets

Hematological Disease Markets

1 Report Overview

1.1 Study Scope

1.2 Market Analysis by Type

1.2.1 Global Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Market Size Growth Rate by Type: 2020 VS 2024 VS 2031

1.2.2 Chemotherapy

1.2.3 Radiation Therapy

1.2.4 Others

1.3 Market by Application

1.3.1 Global Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Market Growth by Application: 2020 VS 2024 VS 2031

1.3.2 Hospitals

1.3.3 Clinics

1.3.4 Ambulatory Surgical Centers

1.3.5 Others

1.4 Assumptions and Limitations

1.5 Study Objectives

1.6 Years Considered

2 Global Growth Trends

2.1 Global Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Market Perspective (2020-2031)

2.2 Global Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Growth Trends by Region

2.2.1 Global Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Market Size by Region: 2020 VS 2024 VS 2031

2.2.2 Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Historic Market Size by Region (2020-2025)

2.2.3 Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Forecasted Market Size by Region (2026-2031)

2.3 Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Market Dynamics

2.3.1 Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Industry Trends

2.3.2 Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Market Drivers

2.3.3 Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Market Challenges

2.3.4 Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Market Restraints

3 Competition Landscape by Key Players

3.1 Global Top Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Players by Revenue

3.1.1 Global Top Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Players by Revenue (2020-2025)

3.1.2 Global Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Revenue Market Share by Players (2020-2025)

3.2 Global Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

3.3 Global Key Players Ranking by Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Revenue

3.4 Global Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Market Concentration Ratio

3.4.1 Global Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Market Concentration Ratio (CR5 and HHI)

3.4.2 Global Top 10 and Top 5 Companies by Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Revenue in 2024

3.5 Global Key Players of Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Head office and Area Served

3.6 Global Key Players of Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment, Product and Application

3.7 Global Key Players of Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment, Date of Enter into This Industry

3.8 Mergers & Acquisitions, Expansion Plans

4 Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Breakdown Data by Type

4.1 Global Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Historic Market Size by Type (2020-2025)

4.2 Global Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Forecasted Market Size by Type (2026-2031)

5 Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Breakdown Data by Application

5.1 Global Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Historic Market Size by Application (2020-2025)

5.2 Global Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Forecasted Market Size by Application (2026-2031)

6 North America

6.1 North America Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Market Size (2020-2031)

6.2 North America Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Market Growth Rate by Country: 2020 VS 2024 VS 2031

6.3 North America Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Market Size by Country (2020-2025)

6.4 North America Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Market Size by Country (2026-2031)

6.5 United States

6.6 Canada

7 Europe

7.1 Europe Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Market Size (2020-2031)

7.2 Europe Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Market Growth Rate by Country: 2020 VS 2024 VS 2031

7.3 Europe Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Market Size by Country (2020-2025)

7.4 Europe Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Market Size by Country (2026-2031)

7.5 Germany

7.6 France

7.7 U.K.

7.8 Italy

7.9 Russia

7.10 Nordic Countries

8 Asia-Pacific

8.1 Asia-Pacific Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Market Size (2020-2031)

8.2 Asia-Pacific Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Market Growth Rate by Region: 2020 VS 2024 VS 2031

8.3 Asia-Pacific Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Market Size by Region (2020-2025)

8.4 Asia-Pacific Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Market Size by Region (2026-2031)

8.5 China

8.6 Japan

8.7 South Korea

8.8 Southeast Asia

8.9 India

8.10 Australia

9 Latin America

9.1 Latin America Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Market Size (2020-2031)

9.2 Latin America Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Market Growth Rate by Country: 2020 VS 2024 VS 2031

9.3 Latin America Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Market Size by Country (2020-2025)

9.4 Latin America Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Market Size by Country (2026-2031)

9.5 Mexico

9.6 Brazil

10 Middle East & Africa

10.1 Middle East & Africa Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Market Size (2020-2031)

10.2 Middle East & Africa Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Market Growth Rate by Country: 2020 VS 2024 VS 2031

10.3 Middle East & Africa Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Market Size by Country (2020-2025)

10.4 Middle East & Africa Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Market Size by Country (2026-2031)

10.5 Turkey

10.6 Saudi Arabia

10.7 UAE

11 Key Players Profiles

11.1 Roche

11.1.1 Roche Company Details

11.1.2 Roche Business Overview

11.1.3 Roche Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Introduction

11.1.4 Roche Revenue in Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Business (2020-2025)

11.1.5 Roche Recent Development

11.2 Novartis

11.2.1 Novartis Company Details

11.2.2 Novartis Business Overview

11.2.3 Novartis Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Introduction

11.2.4 Novartis Revenue in Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Business (2020-2025)

11.2.5 Novartis Recent Development

11.3 Seattle Genetics

11.3.1 Seattle Genetics Company Details

11.3.2 Seattle Genetics Business Overview

11.3.3 Seattle Genetics Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Introduction

11.3.4 Seattle Genetics Revenue in Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Business (2020-2025)

11.3.5 Seattle Genetics Recent Development

11.4 Merck

11.4.1 Merck Company Details

11.4.2 Merck Business Overview

11.4.3 Merck Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Introduction

11.4.4 Merck Revenue in Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Business (2020-2025)

11.4.5 Merck Recent Development

11.5 Bristol-Myers Squibb

11.5.1 Bristol-Myers Squibb Company Details

11.5.2 Bristol-Myers Squibb Business Overview

11.5.3 Bristol-Myers Squibb Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Introduction

11.5.4 Bristol-Myers Squibb Revenue in Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Business (2020-2025)

11.5.5 Bristol-Myers Squibb Recent Development

11.6 Genmab AS

11.6.1 Genmab AS Company Details

11.6.2 Genmab AS Business Overview

11.6.3 Genmab AS Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Introduction

11.6.4 Genmab AS Revenue in Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Business (2020-2025)

11.6.5 Genmab AS Recent Development

11.7 Takeda Pharmaceutical

11.7.1 Takeda Pharmaceutical Company Details

11.7.2 Takeda Pharmaceutical Business Overview

11.7.3 Takeda Pharmaceutical Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Introduction

11.7.4 Takeda Pharmaceutical Revenue in Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Business (2020-2025)

11.7.5 Takeda Pharmaceutical Recent Development

11.8 Eisai Co., Ltd.

11.8.1 Eisai Co., Ltd. Company Details

11.8.2 Eisai Co., Ltd. Business Overview

11.8.3 Eisai Co., Ltd. Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Introduction

11.8.4 Eisai Co., Ltd. Revenue in Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Business (2020-2025)

11.8.5 Eisai Co., Ltd. Recent Development

11.9 Cellerant Therapeutics

11.9.1 Cellerant Therapeutics Company Details

11.9.2 Cellerant Therapeutics Business Overview

11.9.3 Cellerant Therapeutics Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Introduction

11.9.4 Cellerant Therapeutics Revenue in Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Business (2020-2025)

11.9.5 Cellerant Therapeutics Recent Development

12 Analyst's Viewpoints/Conclusions

13 Appendix

13.1 Research Methodology

13.1.1 Methodology/Research Approach

13.1.1.1 Research Programs/Design

13.1.1.2 Market Size Estimation

13.1.1.3 Market Breakdown and Data Triangulation

13.1.2 Data Source

13.1.2.1 Secondary Sources

13.1.2.2 Primary Sources

13.2 Author Details

13.3 Disclaimer

FEATURED COMPANIES

Roche

Novartis

Seattle Genetics

Merck

Bristol–Myers Squibb

Genmab AS

Takeda Pharmaceutical

Eisai Co Ltd

Cellerant Therapeutics

List of Tables

Table 1. Global Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Market Size Growth Rate by Type (US$ Million): 2020 VS 2024 VS 2031

Table 2. Key Players of Chemotherapy

Table 3. Key Players of Radiation Therapy

Table 4. Key Players of Others

Table 5. Global Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031

Table 6. Global Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Market Size by Region (US$ Million): 2020 VS 2024 VS 2031

Table 7. Global Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Market Size by Region (2020-2025) & (US$ Million)

Table 8. Global Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Market Share by Region (2020-2025)

Table 9. Global Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Forecasted Market Size by Region (2026-2031) & (US$ Million)

Table 10. Global Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Market Share by Region (2026-2031)

Table 11. Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Market Trends

Table 12. Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Market Drivers

Table 13. Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Market Challenges

Table 14. Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Market Restraints

Table 15. Global Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Revenue by Players (2020-2025) & (US$ Million)

Table 16. Global Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Market Share by Players (2020-2025)

Table 17. Global Top Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment as of 2024)

Table 18. Ranking of Global Top Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Companies by Revenue (US$ Million) in 2024

Table 19. Global 5 Largest Players Market Share by Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Revenue (CR5 and HHI) & (2020-2025)

Table 20. Global Key Players of Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment, Headquarters and Area Served

Table 21. Global Key Players of Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment, Product and Application

Table 22. Global Key Players of Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment, Date of Enter into This Industry

Table 23. Mergers & Acquisitions, Expansion Plans

Table 24. Global Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Market Size by Type (2020-2025) & (US$ Million)

Table 25. Global Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Revenue Market Share by Type (2020-2025)

Table 26. Global Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Forecasted Market Size by Type (2026-2031) & (US$ Million)

Table 27. Global Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Revenue Market Share by Type (2026-2031)

Table 28. Global Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Market Size by Application (2020-2025) & (US$ Million)

Table 29. Global Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Revenue Market Share by Application (2020-2025)

Table 30. Global Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Forecasted Market Size by Application (2026-2031) & (US$ Million)

Table 31. Global Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Revenue Market Share by Application (2026-2031)

Table 32. North America Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031

Table 33. North America Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Market Size by Country (2020-2025) & (US$ Million)

Table 34. North America Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Market Size by Country (2026-2031) & (US$ Million)

Table 35. Europe Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031

Table 36. Europe Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Market Size by Country (2020-2025) & (US$ Million)

Table 37. Europe Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Market Size by Country (2026-2031) & (US$ Million)

Table 38. Asia-Pacific Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Market Size Growth Rate by Region (US$ Million): 2020 VS 2024 VS 2031

Table 39. Asia-Pacific Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Market Size by Region (2020-2025) & (US$ Million)

Table 40. Asia-Pacific Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Market Size by Region (2026-2031) & (US$ Million)

Table 41. Latin America Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031

Table 42. Latin America Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Market Size by Country (2020-2025) & (US$ Million)

Table 43. Latin America Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Market Size by Country (2026-2031) & (US$ Million)

Table 44. Middle East & Africa Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031

Table 45. Middle East & Africa Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Market Size by Country (2020-2025) & (US$ Million)

Table 46. Middle East & Africa Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Market Size by Country (2026-2031) & (US$ Million)

Table 47. Roche Company Details

Table 48. Roche Business Overview

Table 49. Roche Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Product

Table 50. Roche Revenue in Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Business (2020-2025) & (US$ Million)

Table 51. Roche Recent Development

Table 52. Novartis Company Details

Table 53. Novartis Business Overview

Table 54. Novartis Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Product

Table 55. Novartis Revenue in Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Business (2020-2025) & (US$ Million)

Table 56. Novartis Recent Development

Table 57. Seattle Genetics Company Details

Table 58. Seattle Genetics Business Overview

Table 59. Seattle Genetics Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Product

Table 60. Seattle Genetics Revenue in Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Business (2020-2025) & (US$ Million)

Table 61. Seattle Genetics Recent Development

Table 62. Merck Company Details

Table 63. Merck Business Overview

Table 64. Merck Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Product

Table 65. Merck Revenue in Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Business (2020-2025) & (US$ Million)

Table 66. Merck Recent Development

Table 67. Bristol-Myers Squibb Company Details

Table 68. Bristol-Myers Squibb Business Overview

Table 69. Bristol-Myers Squibb Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Product

Table 70. Bristol-Myers Squibb Revenue in Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Business (2020-2025) & (US$ Million)

Table 71. Bristol-Myers Squibb Recent Development

Table 72. Genmab AS Company Details

Table 73. Genmab AS Business Overview

Table 74. Genmab AS Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Product

Table 75. Genmab AS Revenue in Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Business (2020-2025) & (US$ Million)

Table 76. Genmab AS Recent Development

Table 77. Takeda Pharmaceutical Company Details

Table 78. Takeda Pharmaceutical Business Overview

Table 79. Takeda Pharmaceutical Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Product

Table 80. Takeda Pharmaceutical Revenue in Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Business (2020-2025) & (US$ Million)

Table 81. Takeda Pharmaceutical Recent Development

Table 82. Eisai Co., Ltd. Company Details

Table 83. Eisai Co., Ltd. Business Overview

Table 84. Eisai Co., Ltd. Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Product

Table 85. Eisai Co., Ltd. Revenue in Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Business (2020-2025) & (US$ Million)

Table 86. Eisai Co., Ltd. Recent Development

Table 87. Cellerant Therapeutics Company Details

Table 88. Cellerant Therapeutics Business Overview

Table 89. Cellerant Therapeutics Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Product

Table 90. Cellerant Therapeutics Revenue in Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Business (2020-2025) & (US$ Million)

Table 91. Cellerant Therapeutics Recent Development

Table 92. Research Programs/Design for This Report

Table 93. Key Data Information from Secondary Sources

Table 94. Key Data Information from Primary Sources

Table 95. Authors List of This Report

List of Figures

Figure 1. Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Picture

Figure 2. Global Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Market Size Comparison by Type (2020-2031) & (US$ Million)

Figure 3. Global Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Market Share by Type: 2024 VS 2031

Figure 4. Chemotherapy Features

Figure 5. Radiation Therapy Features

Figure 6. Others Features

Figure 7. Global Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Market Size by Application (2020-2031) & (US$ Million)

Figure 8. Global Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Market Share by Application: 2024 VS 2031

Figure 9. Hospitals Case Studies

Figure 10. Clinics Case Studies

Figure 11. Ambulatory Surgical Centers Case Studies

Figure 12. Others Case Studies

Figure 13. Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Report Years Considered

Figure 14. Global Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Market Size (US$ Million), Year-over-Year: 2020-2031

Figure 15. Global Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Market Size, (US$ Million), 2020 VS 2024 VS 2031

Figure 16. Global Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Market Share by Region: 2024 VS 2031

Figure 17. Global Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Market Share by Players in 2024

Figure 18. Global Top Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment as of 2024)

Figure 19. The Top 10 and 5 Players Market Share by Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Revenue in 2024

Figure 20. North America Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 21. North America Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Market Share by Country (2020-2031)

Figure 22. United States Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 23. Canada Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 24. Europe Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 25. Europe Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Market Share by Country (2020-2031)

Figure 26. Germany Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 27. France Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 28. U.K. Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 29. Italy Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 30. Russia Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 31. Nordic Countries Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 32. Asia-Pacific Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 33. Asia-Pacific Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Market Share by Region (2020-2031)

Figure 34. China Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 35. Japan Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 36. South Korea Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 37. Southeast Asia Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 38. India Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 39. Australia Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 40. Latin America Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 41. Latin America Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Market Share by Country (2020-2031)

Figure 42. Mexico Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 43. Brazil Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 44. Middle East & Africa Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 45. Middle East & Africa Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Market Share by Country (2020-2031)

Figure 46. Turkey Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 47. Saudi Arabia Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 48. UAE Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 49. Roche Revenue Growth Rate in Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Business (2020-2025)

Figure 50. Novartis Revenue Growth Rate in Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Business (2020-2025)

Figure 51. Seattle Genetics Revenue Growth Rate in Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Business (2020-2025)

Figure 52. Merck Revenue Growth Rate in Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Business (2020-2025)

Figure 53. Bristol-Myers Squibb Revenue Growth Rate in Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Business (2020-2025)

Figure 54. Genmab AS Revenue Growth Rate in Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Business (2020-2025)

Figure 55. Takeda Pharmaceutical Revenue Growth Rate in Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Business (2020-2025)

Figure 56. Eisai Co., Ltd. Revenue Growth Rate in Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Business (2020-2025)

Figure 57. Cellerant Therapeutics Revenue Growth Rate in Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Business (2020-2025)

Figure 58. Bottom-up and Top-down Approaches for This Report

Figure 59. Data Triangulation

Figure 60. Key Executives Interviewed

SELECT A FORMAT

Added to Cart

Single User

Electronic (PDF)

$2900

This license allows only one user to access the PDF.

Multi User

Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together

Enterprise User

Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

Cutaneous T Cell Lymphoma CTCL Treatment Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Peripheral T cell lymphoma Therapy Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Cutaneous Cell Lymphoma Treatment Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Peripheral T Cell Lymphoma PTCL Treatment Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Acute Lymphocytic Leukemia ALL Treatment Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global Acute Lymphoblastic Leukemia Drug Market Research Report 2024

Cutaneous B Cell Lymphoma Treatment Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Lymphoma Treatment Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Intraocular Lymphoma Treatment Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global Indolent Lymphoma Treatment Market Research Report 2025

Lymphoma Treatment Drug Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Hematological Malignancies Treatment Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global Mantle Cell Lymphoma Treatment Market Research Report 2025

CAR T Cell Immunotherapies for Cancer Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global B Cell Chronic Lymphocytic Leukemia Treatment Market Research Report 2024

Global CAR T Cellular Immunotherapy Drug Market Research Report 2024

Global Hematological Malignancy Treatment Market Research Report 2025

CAR T Therapy in Haematological Malignancy Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Cancers Immunotherapy Drugs Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

RELATED REPORTS

Global Fixation Device for Radiotherapy Market Research Report 2025

120 Pages

Type: Report

Code: QYRE-Auto-4H16852

Thu Sep 25 00:00:00 UTC 2025

Add to Cart

Global Group A Streptococcus for Injection Market Research Report 2025

120 Pages

Type: Report

Code: QYRE-Auto-37K16619

Thu Sep 25 00:00:00 UTC 2025

Add to Cart

Global Boron Neutron Capture Therapy System Market Research Report 2025

120 Pages

Type: Report

Code: QYRE-Auto-30U16301

Thu Sep 25 00:00:00 UTC 2025

Add to Cart

Global Radioactive Glass Microsphere Market Research Report 2025

120 Pages

Type: Report

Code: QYRE-Auto-2G16953

Thu Sep 25 00:00:00 UTC 2025

Add to Cart

aluates Reports

Support Contacts

U.S. (TOLL FREE)

+1 (425) 388-2538

sales@valuates.com

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

CONTACT
FAQ

POLICES

THE COMPANY

ABOUT US

CUSTOMER SUPPORT

CONTACT
FAQ

OUR PRODUCTS

POLICES

Sitemap - Privacy Policy - Terms & Conditions